Indication
COVID-19 ARDS
10 clinical trials
14 products
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Two Parallel Groups, International Multicenter Trial to Evaluate the Effect of Plerixafor in Acute Respiratory Failure Related to COVID-19.Status: Withdrawn, Estimated PCD: 2022-10-01
Product
PlerixaforClinical trial
A Multi-center, Randomized, Double-blind, Placebo-controlled, Study to Assess the Safety, Tolerability, Pharmacodynamics (PD) and Efficacy of TTI-0102 for the Treatment of Patients With Mild to Moderate COVID-19Status: Not yet recruiting, Estimated PCD: 2025-06-01
Product
PlaceboProduct
TTI-0102Clinical trial
Safety and Efficacy of Inhaled XW001 (Interleukin 29 Analog for Nebulization) For Hospitalized COVID-19 Patients Requiring Oxygen Therapy: A Multiregional, Randomized, Double-blind, Placebo-controlled StudyStatus: Withdrawn, Estimated PCD: 2022-03-10
Product
EV-PureClinical trial
Safety and Effectiveness of Placental Derived Exosomes and Umbilical Cord Mesenchymal Stem Cells in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) Associated With the Novel Corona Virus Infection (COVID-19)Status: Recruiting, Estimated PCD: 2023-10-01
Product
XW001Clinical trial
A Multicentric Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Centhaquine as an Adjuvant to the Standard of Care in COVID-19 Patients With Moderate to Severe Acute Respiratory Distress SyndromeStatus: Not yet recruiting, Estimated PCD: 2025-10-31
Product
Normal SalineProduct
CenthaquineProduct
BromAcClinical trial
Safety of Nebulised Delivery of BromAc® (Bromelain & Acetylcysteine) in Healthy Volunteers: a Potential Treatment for Severe COVID-19Status: Completed, Estimated PCD: 2022-08-14
Product
AV-001Clinical trial
An Interventional, Phase III, Double-blind, Randomized, Controlled, Parallel-group, Multi-site, Clinical Trial Evaluating the Efficacy and Safety of Qutenza® in Subjects With Post-surgical Neuropathic PainStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Interleukine 6 (IL6) Assay for Predicting Failure of Spontaneous Breathing in Patients With COVID-19 Acute Respiratory Distress SyndromeStatus: Terminated, Estimated PCD: 2022-03-24
Product
IL6Product
CRP and PCT assessmentClinical trial
Safety and Therapeutic Efficacy of Cyclosporine Plus Standard of Care Treatment on ARDS in COVID -19 Patients at Alexandria University Hospitals in 2021: a Comparative StudyStatus: Completed, Estimated PCD: 2022-09-09
Product
cyclosporineClinical trial
Personalized Targeted Immunomodulation in Patients With ARDS Related to COVID19 and Future Pandemic PathogensStatus: Completed, Estimated PCD: 2022-02-01
Product
Standard of care